9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV
© 2015 Taylor & Francis. Human papillomavirus (HPV) is the causative agent of nearly all cervical cancer cases as well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers, making it responsible for approximately 5% of the global cancer burden. The first-gener...
Saved in:
Main Authors: | Punnee Pitisuttithum, Christine Velicer, Alain Luxembourg |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/35347 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Immunogenicity and safety of a 9-valent HPV vaccine
by: Pierre Van Damme, et al.
Published: (2018) -
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
by: Lone K. Petersen, et al.
Published: (2018) -
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
by: E. A. Joura, et al.
Published: (2018) -
Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV- 27, and HPV-57 group, which is associated with common warts
by: Chan, S.-Y., et al.
Published: (2014) -
Immunogenicity of the 9-valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys Vs A 3-Dose Regimen in Women
by: Ole Erik Iversen, et al.
Published: (2018)